If a patient tests positive for chlamydia, should the sexual partner be tested and evaluated, or should they receive empiric treatment only?

Partner Management for Chlamydia: Empiric Treatment Without Testing

Sexual partners of patients with confirmed chlamydia should receive empiric antibiotic treatment immediately without waiting for their own test results, though testing should still be performed concurrently. This approach prioritizes preventing complications, ongoing transmission, and loss to follow-up over the theoretical benefit of confirming infection before treatment.1, 2

Evidence Supporting Empiric Partner Treatment

High Infection Rates Among Contacts

• Partners of chlamydia-positive patients have substantially elevated infection rates: 34-40% of female contacts, 36% of heterosexual male contacts, and 24% of MSM contacts test positive for chlamydia.3, 4
• The CDC explicitly states that sex partners from the preceding 60 days must be evaluated, tested, and treated empirically, regardless of symptom status.1, 2
• Even when the most recent sexual contact occurred more than 60 days before diagnosis, that partner should still receive empiric treatment.1

Risks of Delaying Treatment

• Waiting for test results increases the risk of disease complications, ongoing transmission, and loss to follow-up.2
• In one pediatric emergency department study, 43% of patients who tested positive but did not receive empiric treatment had difficulties with follow-up, highlighting the real-world consequences of delayed treatment.5
• The adverse consequences of treating an uninfected partner are primarily psychosocial, while the antibiotics used (azithromycin or doxycycline) have relatively mild and uncommon side effects.2

Why Testing Should Still Be Performed

Despite empiric treatment, partners should undergo concurrent NAAT testing for several critical reasons:2

• Confirms infection status and provides firm grounds for partner notification of the contact's other sexual partners
• Identifies co-infections: 20-40% of chlamydia-positive patients in high-prevalence settings also have gonorrhea, requiring additional treatment with ceftriaxone.2, 4
• Enables appropriate follow-up care if symptoms develop or reinfection occurs
• Supports public health surveillance and contact tracing efforts

Additional STI Screening Required

All partners being evaluated should receive comprehensive testing at the initial visit:2

• Gonorrhea NAAT (same specimen can test for both chlamydia and gonorrhea)
• Syphilis serology
• HIV testing

In settings where gonorrhea prevalence exceeds 5%, treat presumptively for both infections with ceftriaxone 250 mg IM plus azithromycin 1 g orally as a single dose.2

Recommended Empiric Treatment Regimens

Partners should receive the same first-line treatment as index patients:1, 2

• Azithromycin 1 g orally as a single dose (preferred when compliance is uncertain; allows directly observed therapy)
• Doxycycline 100 mg orally twice daily for 7 days (equally effective; lower cost)

Both regimens achieve 97-98% cure rates.2

Sexual Abstinence and Timing

• Partners must abstain from all sexual activity for 7 days after initiating treatment and until all symptoms resolve.1, 2, 6
• The index patient should also abstain for 7 days after treatment and until all partners have completed therapy to prevent reinfection.1, 6

Follow-Up Recommendations

• Test-of-cure is NOT recommended for non-pregnant partners treated with recommended regimens unless compliance is questionable or symptoms persist.1, 2, 7
• Retest at 3 months is strongly recommended for all treated partners due to high reinfection rates (up to 39% in some populations).1, 2, 7
• This 3-month retest screens for reinfection, not treatment failure, and should be performed regardless of whether the partner believes the index patient was treated.1, 7

Common Pitfalls to Avoid

• Do NOT wait for partner test results before treating—the increased prevalence among contacts warrants immediate empiric therapy.2
• Do NOT assume partners were treated—directly verify or use expedited partner therapy strategies.2
• Do NOT omit gonorrhea testing—co-infection rates are substantial and require different treatment.2, 4
• Do NOT skip the 3-month retest—most "persistent infections" are actually reinfections from untreated or inadequately treated partners.7

Alternative Approach: Expedited Partner Therapy (EPT)

In situations where partners cannot or will not present for evaluation, EPT allows delivery of medication or prescriptions directly to the partner:1

• Advantages: Increases treatment rates; reduces reinfection of index patient
• Disadvantages: Misses opportunity to test for other STIs (10% of chlamydia contacts have gonorrhea; some have syphilis or HIV); results in unnecessary antibiotic use in the 60-66% of contacts who test negative4

EPT should be considered only when traditional partner evaluation is not feasible, and legal regulations vary by jurisdiction.1

Evidence Quality Note

The recommendation for empiric partner treatment is based on strong CDC guideline consensus (1998-2014) supported by observational data showing high positivity rates among contacts and poor follow-up when treatment is delayed.1, 2 A 2025 Australian study challenged routine treatment of all contacts, showing that selective treatment (treating only those who test positive or have symptoms) reduced unnecessary antibiotic use without increasing loss to follow-up—but this approach requires reliable same-day testing and high patient return rates, which may not be feasible in many settings.8